Premium
KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: A biomarker of cancer biology or a byproduct of patient selection?
Author(s) -
Søreide Kjetil,
Sandvik Oddvar M.,
Søreide Jon A.
Publication year - 2014
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.28979
Subject(s) - colorectal cancer , kras , medicine , biomarker , metastasis , cancer , oncology , mutation , selection (genetic algorithm) , biology , gene , genetics , artificial intelligence , computer science
Patients with colorectal cancer have experienced remarkable progress in a range of surgical and oncologic management strategies over the past few years, with a corresponding improvement in survival. The KRAS mutation may be a biomarker of cancer biology and prognosis, but also reflects patient selection.